Pfizer Unveils Promising Early Data On COVID-19, Sends Moderna Shares Down
Preliminary Results From 45 Subjects
Pfizer and BioNTech appear to have the upper hand on mRNA rivals Moderna, but Phase III results will be the real test.

Pfizer and BioNTech appear to have the upper hand on mRNA rivals Moderna, but Phase III results will be the real test.